Human Butyrylcholinesterase and Acetylcholinesterase Based Catalytic Bioscavengers of Organophosphates

Tech ID: 23948 / UC Case 2014-091-0

BACKGROUND
Exposure to organophosphates (OP) from both pesticides and nerve agents leads to inhibition of acetylcholinesterase (AChE), resulting in a build-up of acetylcholine in the body, and potentially death. The only OP stoichiometric bioscavenger in use today is butyrylcholinesterase (hBChE). Human butyrylcholinesterase (hBChE) specifically and efficiently captures offending OP molecules in the circulation of exposed individuals, sequestering the OP as an inactive conjugate in the plasma.

TECHNOLOGY DESCRIPTION
Researchers at UCSD and The Scripps Research Institute have designed small reactivator molecules that reactivate human butyrylcholinesterase (hBChE) inhibited by OPs in plasma, lungs and intestine of OP exposed individuals in order for single hBChE molecule to repeatedly, covalently, bind and degrade multiple OP molecules effectively depleting OP from the circulation. These are novel antidotes, structurally unrelated to currently used acetylcholinesterase (AChE) reactivators.

They also designed another group of small reactivator molecules to pair with particular mutant hAChE to interact effectively with OP- mutant hAChE inhibited by OPs in order for single mutant hAChE molecule to repeatedly, covalently bind and degrade multiple OP molecules, thus effectively depleting the OP from the circulation. One pair is designed to increase hAChE’s efficacy against a wider spectrum of OP toxicants including those prone to dealkylation (aging). The other pair is specifically designed to deplete the tabun OP from circulation, and to reactivate tabun-inhibited AChE.

APPLICATIONS
• Treatment of OP-poisoning from accidental and intentional exposure to insecticides. Organophosphates are widely used in agriculture in the US and worldwide.
• A universal antidote to nerve agents as countermeasures to chemical terrorism.
• An antidote to tabun OP. The effective, catalytic OP bioscavenger system for tabun exposure has not been described before.

STATE OF DEVELOPMENT
Proof of principle demonstrated in vitro, in vivo in mice and ex vivo with human blood.

RELATED MATERIALS

PATENT STATUS

<table>
<thead>
<tr>
<th>Country</th>
<th>Type</th>
<th>Number</th>
<th>Dated</th>
<th>Case</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States Of America</td>
<td>Issued Patent</td>
<td>10,172,831</td>
<td>01/08/2019</td>
<td>2014-091</td>
</tr>
<tr>
<td>United States Of America</td>
<td>Published Application</td>
<td>19-0337911</td>
<td>11/07/2019</td>
<td>2012-317</td>
</tr>
<tr>
<td>United States Of America</td>
<td>Published Application</td>
<td>20190119237</td>
<td>04/25/2019</td>
<td>2012-317</td>
</tr>
</tbody>
</table>